ArticleInternational journal of clinical oncology2026
Conversion surgical after neoadjuvant immunochemotherapy achieves survival comparable to initially resectable disease in borderline resectable esophageal cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors have demonstrated preliminary safety and efficacy in treating borderline resectable esophageal squamous cell carcinoma (BR-ESCC). We aimed to compare treatment and survival outcomes between patients with locally advanced resectable ESCC (cT3r) and those with borderline resectable ESCC (cT3br) who underwent surgery following neoadjuvant immunochemotherapy (NICT).
methodsIn this retrospective cohort, 114 patients with clinically staged T3 ESCC who received NICT were screened. Ultimately, 102 patients who underwent surgery were analyzed, categorized into cT3r (n = 62) and cT3br (n = 40) groups based on the likelihood of adjacent vital organ invasion as observed on pre-treatment CT scans.
resultsAmong patients with cT3br disease, the conversion-to-resectability rate after NICT was 76.9% (40/52). Surgical parameters and postoperative complication rates were comparable between the two groups (all P > 0.05). Although the non-R0 resection rate was significantly higher in the cT3br group than in the cT3r group (20.0% vs 3.2%, P = 0.005), no significant differences were observed in postoperative overall survival (OS) or disease-free survival (DFS) between the two groups (3-year OS: 76% vs 67%, P = 0.453; 3-year DFS: 69% vs 47%, P = 0.155). Non-R0 resection was significantly associated with worse OS (P = 0.001) and showed a trend toward association with DFS (P = 0.069).
conclusionIn this single-arm cohort study, NICT demonstrated potential as a conversion therapy for BR-ESCC, yielding promising surgical conversion and survival outcomes that approached those of patients with cT3r disease.
Indexed as
Identifiers
41902901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.